• Marvel Discovery (TSXV:MARV) is starting a new drilling phase at its KLR-Walker Uranium Project
  • The Vancouver mineral explorer will now drill four holes for a total of 2,400 metres on the project
  • Previous drilling intersected 841 parts per million (ppm) Triuranium octoxide (U3O8) over 1.07 metres on the project’s DD Zone
  • All U3O8 discovered during the first phase of drilling was in stringer mineralization along a regional-scale fault
  • Marvel Discovery (MARV) opened trading at $0.06

Marvel Discovery (TSXV:MARV) is starting a new drilling phase at its KLR-Walker Uranium Project in Saskatchewan.

The Vancouver mineral explorer will now drill four holes for a total of 2,400 metres on the project, located in Saskatchewan’s Athabasca Basin.

The company completed 1,343 metres across six diamond drill holes during an earlier spring exploration program.

Previous drilling intersected 841 parts per million (ppm) Triuranium octoxide (U3O8) over 1.07 metres on the project’s DD Zone. Drilling on the nearby Highway Zone returned 553 ppm.

All U3O8 discovered during the first phase of drilling was in stringer mineralization along a regional-scale fault.

“The company is extremely excited about the 2023 Phase II program. We have successfully followed up on historical surface and backpack uranium mineralization along key structures with Phase I,” Marvel Discovery CEO Karim Rayani said in a statement released Thursday.

“Our Phase II program is to test these structures and associated uranium mineralization at depth to unlock the potential presence of a Tier I uranium discovery.”

The company is continuing to operate projects in Ontario, Quebec, Newfoundland and British Columbia, in addition to the Athabasca Basin.

Marvel Discovery (MARV) opened trading at $0.06.

Join the discussion: Find out what everybody’s saying about this stock on the Marvel Discovery Bullboards and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.

More From The Market Online
(Source: VitalHub Corp.)

VitalHub acquires MedCurrent Corp. for $12M

VitalHub (TSX:VHI) has closed its acquisition of MedCurrent Corp. in an all-cash transaction for C$12.0 million.
Medical technician looking into a microscope

Theralase’s bladder cancer drug under investigation in clinical study

Pharma stock Theralase Technologies (TSXV:TLT) announces a significant update on its ongoing bladder cancer clinical study.